|
1
|
Masel EK, Berghoff AS, Füreder LM,
Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U,
Birner P, Bartsch R, et al: Decreased body mass index is associated
with impaired survival in lung cancer patients with brain
metastases: A retrospective analysis of 624 patients. Eur J Cancer
Care (Engl). 26:e127072017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sui T, Liu A and Jiao W: Difference of
lung function retention after segmentectomy and lobectomy. Zhongguo
Fei Ai Za Zhi. 22:178–182. 2019.PubMed/NCBI
|
|
3
|
Wang W, Zhang L, Liu L, Zheng Y, Zhang Y,
Yang S, Shi R and Wang S: Chemosensitizing effect of shRNA-mediated
ERCC1 silencing on a Xuanwei lung adenocarcinoma cell line and its
clinical significance. Oncol Rep. 37:1989–1997. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Levy A, Faivre-Finn C, Hasan B, De Maio E,
Berghoff AS, Girard N, Greillier L, Lantuéjoul S, O'Brien M, Reck
M, et al: Diversity of brain metastases screening and management in
non-small cell lung cancer in Europe: Results of the European
Organisation for Research and Treatment of Cancer Lung Cancer Group
survey. Eur J Cancer. 93:37–46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Majem M, Juan O, Insa A, Reguart N, Trigo
JM, Carcereny E, García-Campelo R, García Y, Guirado M and
Provencio M: SEOM clinical guidelines for the treatment of
non-small cell lung cancer (2018). Clin Transl Oncol. 21:3–17.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng L, Gao E, Zhu F, Wang Y, Zhong J and
An T: A case report on successful third challenge to the
Pemetrexed-based regimen for advanced non-small cell lung cancer.
Zhongguo Fei Ai Za Zhi. 22:395–400. 2019.PubMed/NCBI
|
|
7
|
Zhang Y: Chemotherapy in advanced
non-small cell lung cancer: Present and future. J Int Transl Med.
5:38–44. 2017.
|
|
8
|
Matsufuji H, Shiozaki E, Nakatake Y,
Yoshida K, Kamada K and Matsuo T: A case of slowly progressive
brain metastasis with minor bleeding after removal of and
chemotherapy for non-small cell lung cancer. No Shinkei Geka.
45:339–344. 2017.PubMed/NCBI
|
|
9
|
Farré PL, Scalise GD, Duca RB, Dalton GN,
Massillo C, Porretti J, Graña K, Gardner K, De Luca P and De Siervi
A: CTBP1 and metabolic syndrome induce an mRNA and miRNA expression
profile critical for breast cancer progression and metastasis.
Oncotarget. 9:13848–13858. 2018. View Article : Google Scholar
|
|
10
|
Zhang L, Wang Y, Rashid MH, Liu M, Angara
K, Mivechi NF, Maihle NJ, Arbab AS and Ko L: Malignant pericytes
expressing GT198 give rise to tumor cells through angiogenesis.
Oncotarget. 8:51591–51607. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Glentis A, Oertle P, Mariani P, Chikina A,
El Marjou F, Attieh Y, Zaccarini F, Lae M, Loew D, Dingli F, et al:
Cancer-associated fibroblasts induce metalloprotease-independent
cancer cell invasion of the basement membrane. Nat Commun.
8:9242017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oudin MJ and Weaver VM: Physical and
chemical gradients in the tumor microenvironment regulate tumor
cell invasion, migration, and metastasis. Cold Spring Harb Symp
Quant Biol. 81:189–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shen Y, Su C, Shi Y, Liu X and Zhao L:
Chitosan nanoparticles promoted cancer cell invasion and metastasis
via the massive production of reactive oxygen species. J Biomater
Tissue Eng. 7:484–490. 2017. View Article : Google Scholar
|
|
14
|
Li N, Gao WJ and Liu NS: LncRNA BCAR4
promotes proliferation, invasion and metastasis of non-small cell
lung cancer cells by affecting epithelial-mesenchymal transition.
Eur Rev Med Pharmacol Sci. 21:2075–2086. 2017.PubMed/NCBI
|
|
15
|
Shimizu T, Asakuma M, Tomioka A, Inoue Y,
Hirokawa F, Hayashi M and Uchiyama K: Span-1 and CA19-9 as
predictors of early recurrence and lymph node metastasis for
patients with invasive pancreatic cancer after pancreatectomy. Am
Surg. 84:109–113. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu BP, Guo ZQ, Lin L and Liu Q: Serum
BSP, PSADT, and Spondin-2 levels in prostate cancer and the
diagnostic significance of their ROC curves in bone metastasis. Eur
Rev Med Pharmacol Sci. 21:61–67. 2017.PubMed/NCBI
|
|
17
|
Feng HM, Zhao Y, Zhang JP, Zhang JH, Jiang
P, Li B and Wang C: Expression and potential mechanism of
metabolism-related genes and CRLS1 in non-small cell lung cancer.
Oncol Lett. 15:2661–2668. 2018.PubMed/NCBI
|
|
18
|
Choi H, Ding CG, Lee SB, Durrans A, Ryu S,
Elemento O, Wong S, Altorki NK and Mittal V: Abstract 1159: A novel
HGF-MET paracrine signaling pathway promotes growth and resistance
to chemotherapy in lung cancer. Cancer Res. 74:11592014.
|
|
19
|
Bahrami A, Hasanzadeh M, Hassanian SM,
ShahidSales S, Ghayour-Mobarhan M, Ferns GA and Avan A: The
potential value of the PI3K/Akt/mTOR signaling pathway for
assessing prognosis in cervical cancer and as a target for therapy.
J Cell Biochem. 118:4163–4169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pan JH, Wang HB, Du XF, Liu JY and Zhang
DJ: Polydatin induces human cervical cancer cell apoptosis via
PI3K/AKT/mTOR signaling pathway. Zhongguo Zhong Yao Za Zhi.
42:2345–2349. 2017.PubMed/NCBI
|
|
21
|
Du C, Zhang T, Xiao X, Shi Y, Duan H and
Ren Y: Protease-Activated Receptor-2 promotes kidney tubular
epithelial inflammation by inhibiting autophagy via the
PI3K/Akt/mTOR signalling pathway. Biochem J. 474:2733–2747. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tian B, Zhao Y, Liang T, Ye X, Li Z, Yan
D, Fu Q and Li Y: Curcumin inhibits urothelial tumor development by
suppressing IGF2 and IGF2-mediated PI3K/AKT/mTOR signaling pathway.
J Drug Target. 25:626–636. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu M, Tang R and Jiang Y: Pantoprazole
induces apoptosis of leukemic cells by inhibiting expression of
P-Glycoprotein/Multidrug Resistance-Associated Protein-1 Through
PI3K/AKT/mTOR Signaling. Indian J Hematol Blood Transfus.
33:500–508. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dalal AA, Guerin A, Mutebi A and Culver
KW: Economic analysis of BRAF gene mutation testing in real world
practice using claims data: Costs of single gene versus panel tests
in patients with lung cancer. J Med Econ. 21:649–655. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Toffart AC, Duruisseaux M, Brichon PY,
Pirvu A, Villa J, Selek L, Guillem P, Dumas I, Ferrer L, Levra MG
and Moro-Sibilot D: Operation and chemotherapy: Prognostic factors
for lung cancer with one synchronous metastasis. Ann Thorac Surg.
105:957–965. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang X, Zhang W, Du W, Zhang X, Ren X and
Cao S: Efficacy and survival analysis of apatinib in patients with
advanced nonsquamous non-small cell lung cancer after failure of
first-line treatment. Zhongguo Fei Ai Za Zhi. 20:761–768.
2017.PubMed/NCBI
|
|
28
|
Farnie G, Sotgia F and Lisanti MP: High
mitochondrial mass identifies a sub-population of stem-like cancer
cells that are chemo-resistant. Oncotarget. 6:30472–30486. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Corcoran RB, Dias-Santagata D, Bergethon
K, Iafrate AJ, Settleman J and Engelman JA: BRAF gene amplification
can promote acquired resistance to MEK inhibitors in cancer cells
Harboring the BRAF V600E Mutation. Ence Signaling.
3:ra842010.PubMed/NCBI
|
|
30
|
Ohashi K, Sequist LV, Arcila ME, Moran T,
Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, et
al: Lung cancers with acquired resistance to EGFR inhibitors
occasionally harbor BRAF gene mutations but lack mutations in KRAS,
NRAS, or MEK1. Proc Natl Acad, USA 109. 109:E2127–E2133. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xiao W, Tang H, Wu M, Liao Y, Li K, Li L
and Xu X: Ozone oil promotes wound healing by increasing the
migration of fibroblasts via PI3K/Akt/mTOR signaling pathway.
Biosci Rep. 37:BSR201706582017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Okada K, Nogami A, Ishida S, Akiyama H,
Chen C, Umezawa Y and Miura O: FLT3-ITD induces expression of Pim
kinases through STAT5 to confer resistance to the PI3K/Akt pathway
inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.
Oncotarget. 9:8870–8886. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fu JH, Yang S, Nan CJ, Zhou CC, Lu DQ, Li
S and Mu HQ: miR-182 affects renal cancer cell proliferation,
apoptosis, and invasion by regulating PI3K/AKT/mTOR signaling
pathway. Eur Rev Med Pharmacol Sci. 24:72022020.PubMed/NCBI
|
|
34
|
Guoyin Z, Hao P, Min L, Wei G, Zhe C and
Changquan L: Antihepatocarcinoma effect of Portulaca
oleracea L. in Mice by PI3K/Akt/mTOR and Nrf2/HO-1/NF-κB
Pathway. Evid Based Complement Alternat Med. 2017:82313582017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim GD: Myricetin inhibits angiogenesis by
inducing apoptosis and suppressing PI3K/Akt/mTOR signaling in
endothelial cells. J Cancer Prev. 22:219–227. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen J, Crawford R and Xiao Y: Vertical
inhibition of the PI3K/Akt/mTOR pathway for the treatment of
osteoarthritis. J Cell Biochem. 114:245–249. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang HY, Zhang PN and Sun H: Aberration
of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its
implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol
Reprod Biol. 146:81–86. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cheng H, Shcherba M, Pendurti G, Liang Y,
Piperdi B and Perez-Soler R: Targeting the PI3K/AKT/mTOR pathway:
Potential for lung cancer treatment. Lung Cancer Manag. 3:67–75.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD,
Hu ZB, Shen HB and Shu YQ: Genetic Variants in the
PI3K/PTEN/AKT/mTOR pathway predict Platinum-based chemotherapy
response of advanced non-small cell lung cancers in a Chinese
population. Asian Pac J Cancer Prev. 13:2157–2162. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Q, Lai S, Hou X, Cao W, Zhang Y and
Zhang Z: Protective effects of PI3K/Akt signal pathway induced cell
autophagy in rat knee joint cartilage injury. Am J Transl Res.
10:762–770. 2018.PubMed/NCBI
|
|
42
|
Cheriyan VT, Alsaab H, Sekhar S, Venkatesh
J, Mondal A, Vhora I, Sau S, Muthu M, Polin LA, Levi E, et al: A
CARP-1 functional mimetic compound is synergistic with
BRAF-targeting in non-small cell lung cancers. Oncotarget.
9:29680–29697. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Oei AL, van Leeuwen CM, Ahire VR,
Rodermond HM, Ten Cate R, Westermann AM, Stalpers LJA, Crezee J,
Kok HP, Krawczyk PM, et al: Enhancing synthetic lethality of
PARP-inhibitor and cisplatin in BRCA-proficient Tumour cells with
hyperthermia. Oncotarget. 8:28116–28124. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
An SH, Kang JH, Kim DH and Lee MS: Vitamin
C increases the apoptosis via up-regulation p53 during cisplatin
treatment in human colon cancer cells. BMB Rep. 44:211–216. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Heymann PGB, Henkenius KSE, Ziebart T,
Braun A, Hirthammer K, Halling F, Neff A and Mandic R: Modulation
of tumor cell metabolism by laser photochemotherapy with cisplatin
or zoledronic acid in vitro. Anticancer Res. 38:1291–1301.
2018.PubMed/NCBI
|
|
46
|
Nolte E, Wach S, Silva IT, Lukat S, Ekici
AB, Munkert J, Müller-Uri F, Kreis W, Oliveira Simões CM, Vera J,
et al: A new semisynthetic cardenolide analog
3β-[2-(1-amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG)
affects G2/M cell cycle arrest and miRNA expression profiles and
enhances proapoptotic survivin-2B expression in renal cell
carcinoma cell lines. Oncotarget. 8:11676–11691. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xu C, Sun G, Yuan G, Wang R and Sun X:
Effects of Platycodin D on proliferation, apoptosis and PI3K/Akt
Signal Pathway of Human Glioma U251 Cells. Molecules.
19:21411–21423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Li H, Hu J, Wu S, Wang L, Cao X, Zhang X,
Dai B, Cao M, Shao R, Zhang R, et al: Auranofin-mediated inhibition
of PI3K/AKT/mTOR axis and anticancer activity in non-small cell
lung cancer cells. Oncotarget. 7:3548–3558. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ma HP, Kong WX, Li XY, Li W, Zhang Y and
Wu Y: miRNA-223 is an anticancer gene in human non-small cell lung
cancer through the PI3K/AKT pathway by targeting EGFR. Oncol Rep.
41:1549–1559. 2019.PubMed/NCBI
|
|
50
|
Wang H, Yu Z, Huo S, Chen Z, Ou Z, Mai J,
Ding S and Zhang J: Overexpression of ELF3 facilitates cell growth
and metastasis through PI3K/Akt and ERK signaling pathways in
non-small cell lung cancer. Int J Biochem Cell Biol. 94:98–106.
2018. View Article : Google Scholar : PubMed/NCBI
|
